摘要
目的探讨度洛西汀对抑郁症的疗效和安全性。方法70例抑郁发作患者随机分为度洛西汀组和氟西汀组，每组35例，分别给予度洛西汀和氟西汀治疗，疗程6周。用汉密尔顿抑郁量表（HAMD）评定疗效，用副反应量表（TESS）评定不良反应。结果治疗1—2周，度洛西汀组HAMD评分较氟西汀组显著下降（P均〈0．05=，治疗4～6周，两组相仿（P〉0．05）。度洛西汀组有效率和显效率分别为85．7％和74．3％；氟西汀组有效率与显效率分别为80．o％和71．4％；两组差异无显著性（P〉0．05）。两组间不良反应差异无显著性（P〉0．05）。结论度洛西汀是一种起效较快，且安全、有效的新型抗抑郁药。
[Abstract] objective： To study the efficacy and safety of duloxetine in the treatment of major depression＋ Method： This was a randomized 6 weeks study, 70 outpatients and inpatients diagnosed as depression were randomly assigned into duloxetine group with duloxetine and fluoxetine group with fluoxetine.The efficacy was assessed by Hamilton depression rating scale （HAMD） and the safety was assessed by treatment emergent symptom scale（TESS）. Results： The mean values of HAMD total scores in the study group was significantly lower than that in the control group at the end of the first two weeks （all P〈0.05）, but there was no significant difference between the two groups at the end of week4, 6 （P〉0.05） . Total clinical response rate and effective rate in duloxetine group and fluoxetine group were 85.7%and74.3%; 80.0% and71.4% respectively. No significant difference was found in clinical efficacy between two groups. No obvious difference was found in adverse reactions between two groups. Conclusion： Duloxetine is a safe, effective and rapidly responsive antidepressant.
